InspireMD Announces Appointment of Michael Lawless as Chief Financial Officer

Core Insights - InspireMD, Inc. has appointed Michael Lawless as Chief Financial Officer, effective on or prior to June 30, 2025, succeeding Craig Shore who has held the position for nearly 15 years [1][3] Company Overview - InspireMD is focused on developing the CGuard™ Prime carotid stent system aimed at treating carotid artery disease and preventing strokes [1][7] - The company aims to establish its proprietary MicroNet technology as the industry standard for carotid stenting, emphasizing outstanding acute results and durable, stroke-free long-term outcomes [7] Leadership Transition - Michael Lawless brings extensive experience as a public company CFO, having served as CFO of Lifeward and previously the $200 million Life Sciences unit of Brooks Automation [2] - The CEO of InspireMD expressed enthusiasm for Lawless's expertise to lead the company’s growth, particularly with the upcoming launch of CGuard Prime in the U.S. market [3] Inducement Grant Details - As part of his appointment, Lawless will receive 465,000 shares of restricted stock and stock options to purchase 212,000 shares of common stock, approved by the Compensation Committee [4] - The stock options will vest over three years, with one-third vesting on the first anniversary and the remainder in two equal installments on the second and third anniversaries, contingent on continuous employment [5]